Samfara Acquires Danish Controlled-Substance API Maker Chr. Olesen Synthesis
London – October 02, 2026 -- Samfara has completed the acquisition of Chr. Olesen Synthesis, a Danish manufacturer of controlled-substance active pharmaceutical ingredients, marking the London-based life sciences investment firm's first deal. The transaction sees Samfara buy the business from Chr. Olesen and funds managed by Signet Healthcare Partners, with Chief Executive Thomas Moestrup co-investing alongside the new owner. Financial terms were not disclosed.
Chr. Olesen Synthesis supplies opioid-disorder and ADHD treatment ingredients globally
Based near Copenhagen, Chr. Olesen Synthesis develops and manufactures APIs and advanced intermediates specialising in controlled substances, including buprenorphine for opioid use disorder and lisdexamfetamine for ADHD. Its cGMP-certified plant in Hvidovre has been in commercial production since 2015, supplying pharmaceutical companies across Europe, North America and the Middle East.